Clinical trials: Obstructive Pulmonary Diseases
Chronic Obstructive Pulmonary Disease (COPD)
Tezepelumab COPD Exacerbation Study
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- COURSE (NCT04039113)
- Testing
- Tezepelumab
- Where
- 91 sites in United States, Canada and 8 more
- Volunteers
- 337 people
- Sponsor
- AstraZeneca
Asthma
Progression of Airway Obstruction in Childhood Asthma
Distinct patterns of loss in pulmonary function were identified in children with mild to moderate asthma participating in a 10-year observation period during the NHLBI Childhood Asthma Management Program.
- Trial name
- NCT00873873
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Jewish Health
Asthma, Children
Asthma Action at Erie Trial
The Asthma Action at Erie Trial compares the current best practice in asthma self-management education (certified asthma educator services) to an integrated community health worker (CHW) home intervention in which the real-life…
- Trial name
- NCT02481986
- Testing
- Community Health Worker, Certified asthma educator
- Where
- United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Chronic Obstructive Pulmonary Disease
A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD
The purpose of this study is to determine whether ODSH, when added to conventional treatment, is more effective in treating COPD exacerbations than conventional therapy alone.
- Trial name
- COPD (NCT00457951)
- Testing
- Open-Label, ODSH
- Where
- 38 sites in United States, Belgium and 3 more
- Volunteers
- 158 people
- Sponsor
- Jazz Pharmaceuticals
Asthma, Coronary Artery Disease
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
- Conditions
- Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT00862641
- Testing
- Regadenoson
- Where
- 48 sites in United States
- Volunteers
- 1,009 people
- Sponsor
- Astellas Pharma Inc
COPD, Chronic Musculoskeletal Pain
BRAIN, Symptoms, and Physical Activity in COPD
Persons with COPD have both chronic musculoskeletal pain and dyspnea that require accurate diagnosis and treatment, ultimately to optimize functional status.
- Trial name
- BRAIN-SPA (NCT04291131)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Pulmonary Disease, Chronic Obstructive
A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
The objective of this study is to assess the daily variation in bronchodilator response to an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting anticholinergic (ipratropium) individually and…
- Trial name
- NCT01691482
- Testing
- Albuterol/salbutamol, Ipratropium
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, COPD
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.
- Trial name
- NCT00496470
- Testing
- Symbicort (budesonide/formoterol turbuhaler 320/9ug), Spiriva (tiotropium bromide 18ug)
- Where
- 93 sites in Australia, Canada and 7 more
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
Bronchiolitis
Nebulized Hypertonic Saline for Bronchiolitis
This study aims to examine the effect of nebulized 3% hypertonic saline in the treatment of viral bronchiolitis. The investigators hypothesize that nebulized 3% saline will decrease rate of hospital admission, decrease clinical…
- Trial name
- NCT00619918
- Testing
- Nebulized 3% saline, Nebulized 0.9% saline
- Where
- 2 sites in United States
- Volunteers
- 447 people
- Sponsor
- Children's Hospital Los Angeles
COPD
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium…
- Trial name
- NCT03937479
- Where
- 50 sites in United States
- Volunteers
- 416 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Asthma
A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)
A study to compare the bronchodilatory effect of a single dose of Mometasone Furoate/Formoterol Fumarate (MF/F) pressurized metered dose inhaler (MDI) delivered with and without an AeroChamber Plus® with Flow-Vu® Anti-Static…
- Trial name
- NCT01258803
- Testing
- Formoterol Fumarate DPI, Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer, Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
- Volunteers
- 92 people
- Sponsor
- Organon and Co
Bronchiolitis Obliterans
A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
Approximately 10,000 allogeneic hematopoietic stem cell transplants (HSCT) are performed annually in the US for various indications.
- Trial name
- NCT01163786
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
Asthma
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
To evaluate the dose-response of different doses of CHF 1531 pressurized metered dose inhaler (pMDI) containing formoterol fumarate, on lung function and other clinical outcomes and to identify the optimal dose(s) with regard to…
- Trial name
- FLASH (NCT03086460)
- Testing
- CHF 1531 pMDI, Formoterol Inhalation Solution
- Where
- 10 sites in United States
- Volunteers
- 67 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use
The study is conducted to evaluate the potentially improved patient handling of the ELLIPTA Dry Powder Inhaler (DPI). Therefore, the study aims to evaluate errors encountered by subject with asthma during handling ELLIPTA DPI…
- Trial name
- NCT02794480
- Testing
- ELLIPTA DPI, GSK MDI, AZ MDI
- Where
- 20 sites in United States
- Volunteers
- 324 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)
The study estimates the efficacy and safety of MK0476 and aminophylline intravenous administration in adult participants with acute asthma.
- Trial name
- NCT00442338
- Testing
- montelukast sodium, aminophylline hydrate
- Volunteers
- 91 people
- Sponsor
- Organon and Co
COPD
Dose of Corticosteroids in COPD
COPD (chronic obstructive pulmonary disease) is a long-lasting lung disease usually caused by long-term smoking. COPD can get worse, making people sick enough to need hospitalization.
- Trial name
- DOSE (NCT01742338)
- Testing
- Low Dose Corticosteroids, High Dose Corticosteroids
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Rutgers, The State University of New Jersey
Asthma, Allergic Rhinitis
Effects of Lipoic Acid on Oxidative, Inflammatory and Functional Markers in Asthmatic Patients
The aim of the study is to use the antioxidant and antiinflammatory effects of lipoic acid to improve the quality of life of patients with asthma.
- Trial name
- NCT01221350
- Testing
- Lipoic acid
- Where
- 2 sites in Mexico
- Volunteers
- 55 people
- Sponsor
- Centro Universitario de Ciencias de la Salud, Mexico
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily and umeclidinium bromide (125mcg) once-daily to…
- Trial name
- NCT01772147
- Testing
- Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
- Where
- 55 sites in United States, Chile and 3 more
- Volunteers
- 608 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Integrating Care After Exacerbation of COPD
This clinical trial is designed to determine whether an intervention that provides information to primary care providers about gaps in care for their patients recently discharged from hospital for COPD can reduce hospital…
- Trial name
- InCasE (NCT02021955)
- Testing
- guideline treatment recommendations
- Where
- 2 sites in United States
- Volunteers
- 717 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease
A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease
Objective: Chronic obstructive pulmonary disease (COPD) is a disease with significant morbidity and incurs heavy utilization of healthcare resources.
- Trial name
- NCT01108835
- Testing
- Comprehensive care programme
- Where
- Hong Kong
- Volunteers
- 180 people
- Sponsor
- Chinese University of Hong Kong